Acumen PharmaceuticalsABOS -4.29%34 Cash Ratio is 4.39 as of Mar. 2026, which is 73% below its 10-year median of 15.99. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,387 Biotechnology companies, Acumen Pharmaceuticals ranks better than 60.78% on this metric.
Acumen Pharmaceuticals has a Cash Ratio of 4.39. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Acumen Pharmaceuticals's Cash Ratio or its related term are showing as below:
ABOS'
s Cash Ratio Range Over the Past 10 Years
Min: 1.33 Med: 15.99 Max: 134.29
Current: 4.39
During the past 7 years, Acumen Pharmaceuticals's highest Cash Ratio was 134.29. The lowest was 1.33. And the median was 15.99.
ABOS's Cash Ratio is ranked better than 60.78% of 1387
companies
in the Biotechnology industry
Industry Median: 2.93
vs ABOS: 4.39
Acumen Pharmaceuticals (NAS:ABOS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acumen Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acumen Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Acumen Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acumen Pharmaceuticals (ABOS) has a Cash Ratio of 4.39 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Acumen Pharmaceuticals and its competitors. This is 73% below median its historical median of 15.99. Over the past decade, Acumen Pharmaceuticals' Cash Ratio has ranged from 1.33 to 134.29. According to the industry distribution chart, Acumen Pharmaceuticals ranks #544 out of 1387 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Acumen Pharmaceuticals' Cash Ratio too high?
Acumen Pharmaceuticals' current Cash Ratio of 4.39 is 73% below median its 10-year median of 15.99. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 134.29. The Biotechnology industry median Cash Ratio is 2.93. Acumen Pharmaceuticals' value of 4.39 is 49.8% above this industry median. Based on the distribution chart, Acumen Pharmaceuticals ranks #544 out of 1387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' Cash Ratio compare to YDES and PYXS?
According to the Biotechnology industry distribution chart, Acumen Pharmaceuticals ranks #544 out of 1387 companies for Cash Ratio. This puts Acumen Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 2.93. Acumen Pharmaceuticals' value of 4.39 is 49.8% above this benchmark. Historically, Acumen Pharmaceuticals' own Cash Ratio has ranged from 1.33 to 134.29 over the past decade. While the company's 10-year median is 15.99 vs. the industry median of 2.93, Acumen Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,387 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acumen Pharmaceuticals's current Cash Ratio of 4.39 is 49.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Acumen Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acumen Pharmaceuticals's current Cash Ratio is 4.39, which is 73% below median its own 10-year median of 15.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current Cash Ratio of 4.39. The current Cash Ratio is 4.39, which is 73% below median its 10-year median of 15.99 and 49.8% above the Biotechnology industry median of 2.93. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Cash Ratio is 4.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score
Get the complete analysis for ABOS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABOS has been successfully added to your 
